MammaTyper® is a new tool for subtyping breast cancer.
READ MORE +ABOUT US
Cerca Biotech is the European subsidiary of Shuwen Biotech, a highly reputable and innovative molecular and point of care diagnostics organisation. Shuwen and Cerca are passionate about healthcare and are working to create world-leading innovations in the fields of Oncology and Women’s Health.
Quantitative RT-qPCR assay (CE marked IVD)
Clinical value validated in numerous performance evaluation studies
Clinical value validated in numerous performance evaluation studies
To date, we have had little evidence of whether immunohistochemistry (IHC) can reliably diagnose HER2-low breast cancers. Now a new study has assessed the concordance between expert pathologists using IHC to assess HER2 levels – and the results will do little to reassure patients
New developments in HER2-directed therapies have meant that people with low levels of HER2 expression may benefit from treatments such as trastuzumab deruxtecan (Enhertu). Previously this group would have been deemed ‘HER2-negative’, but now, the distinction of the HER2-low group is clinically important. In light of this, two recent studies have looked at the concordance between different laboratories on HER2-low scoring using immunohistochemistry (IHC). A study of 16 expert pathologists from the UK National Coordinating Committee for Breast Pathology found overall agreement was low. A separate European study, led by researchers at Erasmus University in the Netherlands, came to a similar conclusion.
Ki67 has long been recognised as a valuable prognostic marker in breast cancer, with potential as a predictive marker to guide treatment decisions. A new analysis of a landmark study has revealed more insights into Ki67 and how it relates to other clinico-pathological features. The findings serve as a reminder of the importance of Ki67, but also highlights one of the many challenges of scoring Ki67 using immunohistochemistry.